September, 2018: BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round

September 20, 2018

MORRISTOWN, NJ, (September 17, 2018) BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired Pneumonia (CAP) in Australasia.* The clinical-stage company is focused on a novel approach to address infectious, inflammatory and degenerative diseases through a portfolio built around rhu-pGSN technology. Separately, the company announced that it has closed a $4.1 million equity round.

Read the full press release here: Bioaegis-Therapeutics-Enrolls-Patients-Final

September, 2018: BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

EVENTS

May 23, 2023: Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

COMPANY DETAILS

JOIN OUR TEAM

PRODUCT FAQS

FOLLOW US